Tuesday, August 28, 2018

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Enters Definitive Agreement to Acquire ProstaGene, Announces Key Addition to Leadership Team


Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced its entry into a definitive agreement to acquire privately held ProstaGene, LLC. The company also confirmed that Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., founder and CEO of ProstaGene, will join CytoDyn as interim chief medical officer. Following close of the acquisition, which is expected in November, Pestell will transition to the role of chief medical officer. “We are honored to soon have world-renowned cancer researcher Dr. Richard Pestell join CytoDyn as our Chief Medical Officer, with responsibility for leading all PRO 140 programs in non-HIV indications,” Nader Pourhassan, Ph.D., president and CEO of CytoDyn, stated in the news release. “We also have taken this important next step to acquire ProstaGene, which will allow Dr. Pestell to accelerate his CCR5 antagonist research related to cancer. As previously stated, our objective is to evaluate PRO 140 in expanded indications including certain cancers and immunological indications concurrent with advancing our promising HIV programs.”

To view the full press release, visit http://ibn.fm/bzkm4

About CytoDyn

CytoDyn, Inc. is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn’s lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments. The clinical-stage biotechnology company engages in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. Its product pipeline includes PRO 140, CytoFeline, and Cytolin. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA. For more information, visit the company’s website at www.CytoDyn.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocks has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.


No comments: